Literature DB >> 27240604

The burden of atopic dermatitis in US adults: results from the 2013 National Health and Wellness Survey.

Jennifer Whiteley1, Birol Emir1, Robin Seitzman1, Geoffrey Makinson1.   

Abstract

OBJECTIVES: To characterize comorbidities, health-related quality-of-life (HRQoL), productivity, and healthcare resource use in adults with atopic dermatitis (AD) relative to those without AD, and to evaluate the impact of patient-reported AD severity on these outcomes.
METHODS: Data were from the 2013 National Health and Wellness Survey (NHWS), which collected self-reported information on demographics, comorbidities, HRQoL (SF-36v2 Health Survey), productivity (Work Productivity and Impairment questionnaire [WPAI]), and healthcare utilization, which were weighted to the US general population. The AD cohort consisted of subjects who reported that they experienced AD within the past 12 months (n = 428), and the non-AD cohort included all subjects who did not report experiencing AD (n = 74,572); 366 AD subjects self-reported mild (n = 182) or moderate/severe (n = 184) disease. Univariable and multivariable analyses compared characteristics and outcomes between cohorts and between AD severity levels.
RESULTS: The AD cohort was younger than non-AD cohort (44.3 vs. 46.6 years; P = 0.0033), and had a higher proportion of females (64.4% vs. 51.8%; P < 0.0001). Relative to the non-AD cohort, the AD cohort had a significantly higher prevalence of atopic conditions including nasal allergies (46.4% vs. 19.8%) and asthma (22.4% vs. 7.9%), and neuropsychiatric conditions such as anxiety (42.5% vs. 21.3%) and depression (37.2% vs. 20.9%) (all P < 0.0001). Units of resource use (healthcare practitioner visits, emergency room, hospitalizations) were higher (all P < 0.05) and HRQoL was poorer (P < 0.0001) with AD. On the WPAI, AD employees reported almost twice as much lost work productivity as non-AD employees (30.0% vs. 16.3%; P < 0.0001). No clear differences in outcomes were observed among patient-reported AD severity categories, except greater impairment of work productivity and daily activities in those with moderate/severe AD relative to mild.
CONCLUSIONS: The significant burden associated with AD relative to those without AD suggests an unmet need for more effective management strategies. There also appears to be a need for further characterization of disease severity and its impact on HRQoL.

Entities:  

Keywords:  Atopic dermatitis; burden of illness; health care resource utilization; health related quality of life

Year:  2016        PMID: 27240604     DOI: 10.1080/03007995.2016.1195733

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  22 in total

1.  Association of Inadequately Controlled Disease and Disease Severity With Patient-Reported Disease Burden in Adults With Atopic Dermatitis.

Authors:  Eric L Simpson; Emma Guttman-Yassky; David J Margolis; Steven R Feldman; Abrar Qureshi; Tissa Hata; Vera Mastey; Wenhui Wei; Laurent Eckert; Jingdong Chao; Renée J G Arnold; Tiffany Yu; Francis Vekeman; Mayte Suárez-Fariñas; Abhijit Gadkari
Journal:  JAMA Dermatol       Date:  2018-08-01       Impact factor: 10.282

2.  Impact of Atopic Dermatitis on Work and Activity Impairment in Taiwan.

Authors:  Tom C Chan; Yi-Chun Lin; Yung-Tsu Cho; Chao-Hsiun Tang; Chia-Yu Chu
Journal:  Acta Derm Venereol       Date:  2021-09-22       Impact factor: 3.875

Review 3.  Burden of Atopic Dermatitis in Adults and Adolescents: a Systematic Literature Review.

Authors:  Ahmad N Fasseeh; Baher Elezbawy; Nada Korra; Mohamed Tannira; Hala Dalle; Sandrine Aderian; Sherif Abaza; Zoltán Kaló
Journal:  Dermatol Ther (Heidelb)       Date:  2022-10-05

4.  New and Emerging Therapies for Pediatric Atopic Dermatitis.

Authors:  Henry L Nguyen; Katelyn R Anderson; Megha M Tollefson
Journal:  Paediatr Drugs       Date:  2019-08       Impact factor: 3.930

5.  Clinical and Humanistic Burden of Atopic Dermatitis in Europe: Analyses of the National Health and Wellness Survey.

Authors:  Thomas Luger; William A Romero; David Gruben; Timothy W Smith; Amy Cha; Maureen P Neary
Journal:  Dermatol Ther (Heidelb)       Date:  2022-03-28

6.  Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults.

Authors:  Andreas Kuznik; Gaëlle Bégo-Le-Bagousse; Laurent Eckert; Abhijit Gadkari; Eric Simpson; Christopher N Graham; LaStella Miles; Vera Mastey; Puneet Mahajan; Sean D Sullivan
Journal:  Dermatol Ther (Heidelb)       Date:  2017-09-20

7.  Burden of Atopic Dermatitis in the United States: Analysis of Healthcare Claims Data in the Commercial, Medicare, and Medi-Cal Databases.

Authors:  Sulena Shrestha; Raymond Miao; Li Wang; Jingdong Chao; Huseyin Yuce; Wenhui Wei
Journal:  Adv Ther       Date:  2017-07-13       Impact factor: 3.845

8.  The burden of chronic spontaneous urticaria is substantial: Real-world evidence from ASSURE-CSU.

Authors:  M Maurer; M Abuzakouk; F Bérard; W Canonica; H Oude Elberink; A Giménez-Arnau; C Grattan; K Hollis; A Knulst; J-P Lacour; C Lynde; A Marsland; D McBride; A Nakonechna; J Ortiz de Frutos; C Proctor; G Sussman; C Sweeney; H Tian; K Weller; D Wolin; M-M Balp
Journal:  Allergy       Date:  2017-07-10       Impact factor: 13.146

Review 9.  Comorbidities of Atopic Dermatitis: Beyond Rhinitis and Asthma.

Authors:  Yuki M F Andersen; Alexander Egeberg; Lone Skov; Jacob P Thyssen
Journal:  Curr Dermatol Rep       Date:  2017-01-21

10.  Basal serum cortisol and adrenocorticotropic hormone levels in patients with atopic dermatitis.

Authors:  Zohreh Tehranchinia; Hoda Rahimi; Sara Lotfi
Journal:  Dermatol Pract Concept       Date:  2017-10-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.